Raymond James initiated coverage of Liquidia (LQDA) with an Outperform rating and $27 price target. Yutrepia’s ability to safely dose well beyond the target maintenance dose of United Therapeutics’ (UTHR) Tyvaso should make it a strong competitor in both pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, the analyst tells investors in a research note. The firm thinks Yutrepia is likely to see potential approval in 2025 “or even sooner.” Shares of Liquidia are up 3% to $14.19 in premarket trading.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Liquidia Announces Poster Presentations at the PHA 2024 International PH Conference and Scientific Sessions
- Court filing in United/FDA case may portend decision on Yutrepia, says Needham
- Liquidia reports Q2 EPS (37c), consensus (34c)
- Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Liquidia Technologies call volume above normal and directionally bullish
Questions or Comments about the article? Write to editor@tipranks.com